SCHEMBL4899989

SCHEMBL4899989

COC(=O)c1ccc(Cl)nc1Nc1ccccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.44
▸ GRM5 P41594 4/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ NPC1 O15118 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ GAA P10253 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ TUBB4A P04350 1/20 0.42
▸ TUBB P07437 1/20 0.42
▸ TUBA3C P0DPH7 1/20 0.42
▸ TUBA1B P68363 1/20 0.42
▸ TUBA4A P68366 1/20 0.42
▸ TUBB4B P68371 1/20 0.42
▸ TUBB3 Q13509 1/20 0.42
▸ TUBB2A Q13885 1/20 0.42
▸ TUBB8 Q3ZCM7 1/20 0.42
▸ TUBA3E Q6PEY2 1/20 0.42
▸ TUBA1A Q71U36 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4892317 0.84 MECP2 (0.43) KDM4EGRM5SMN1; SMN2NPC1RAB9A
SCHEMBL4895247 0.83 GRM5 (0.43) GRM5SMN1; SMN2NPC1RAB9AGAA
SCHEMBL4892327 0.79 SMN1; SMN2 (0.45) KDM4ESMN1; SMN2NPC1RAB9AGAA
SCHEMBL1169882 0.78 TUBB4A (0.51) KDM4ESMN1; SMN2NPC1RAB9AGAA
SCHEMBL30275925 0.77 ALDH1A1 (0.46) KDM4ESMN1; SMN2NPC1RAB9ATUBB4A
SCHEMBL28990216 0.77 ALDH1A1 (0.46) KDM4ESMN1; SMN2NPC1RAB9ATUBB4A
SCHEMBL29394920 0.76 KDM4E (0.60) KDM4ESMN1; SMN2NPC1RAB9AGAA
SCHEMBL29173384 0.75 GRM5 (0.58) GRM5SMN1; SMN2NPC1RAB9ACDK5
SCHEMBL21468835 0.75 TUBB4A (0.49) KDM4ESMN1; SMN2NPC1RAB9AGAA
SCHEMBL17668093 0.75 TUBB4A (0.49) KDM4ESMN1; SMN2NPC1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108600-A1 Polycyclic Pyridines as Potassium Ion Channel Modulators ICAGEN, INC. (US) 2008-05-08 — — US disclosed
EP-1737852-A2 POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS Icagen, Inc. (US) 2007-01-03 — — EP disclosed
WO-2005100349-A2 POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS ICAGEN, INC. (US) 2005-10-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108600-A1 Polycyclic Pyridines as Potassium Ion Channel Modulators KCNJ2, KCNH2, KCNQ1 KDM4E 542/4885GRM5 392/4885SMN1; SMN2 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback